Free shipping on all orders over $ 500
Diphenyleneiodonium chloride (DPI) is an irreversible inhibitor of iNOS and eNOS with IC50 values of 50 nM and 0.3 µM, respectively. DPI chloride has been used to inhibit other flavoenzymes such as neutrophil NADPH oxidase and to bind strongly to flavoproteins. DPI chloride is thus a powerful and specific inhibitor of several important enzymes, including NADPH cytochrome P450 oxidoreductase, NADPH oxidases and NADPH-ubiquinone oxidoreductase.
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Molecular Weight | 314.55 |
| Formula | C12H8I.Cl |
| CAS Number | 4673-26-1 |
| Purity | >98% |
| Solubility | DMSO 6 mg/mL (with warming) |
| Storage | at -20°C |
| Related TRP Channel Products |
|---|
| TRPM4-IN-1
Trpm4-in-1 (CBA) is an effective and selective cationic channel TRPM4 inhibitor with an IC50 of 1.5 μM. |
| GFB-8438
GFB-8438 is a potent subtype selective TRPC5 inhibitor against hTRPC5 and hTRPC4 IC50 0.18 and 0.29 μM, respectively. GFB-8438 has good selectivity for TRPC6, other members of the TRP family, NaV1.5, and limited activity against hERG channels. Protective effect of GFB-8438 on mouse podocytes. |
| Mavatrep
Mavatrep is an orally active TRPV1 antagonist with high affinity for the hTRPV1 channel, inhibits the binding of the TRPV1 agonist to [3H]-Resiniferatoxin (Ki=6.5 nM), and has a low effect on the enzymatic activity of CYP subtypes 3A4, 1A2, and 2D6. |
| JNJ-17203212
JNJ-17203212 is a selective, highly effective, competitive TRPV1 antagonist. JNJ-17203212 was developed for research on pain management, such as migraines. |
| Asivatrep
Asivatrep (PAC-14028) is a highly selective transient receptor potential vanilla acid subtype 1 (TRPV1) antagonist. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
